U.S. Colorectal Cancer Markets - Patient OutlookFrost & SullivanDecember 15, 2006 36 Pages - SKU: MC1461624 |
| Countries covered: United States Research Overview The Frost & Sullivan research service titled U.S. Colorectal Cancer Markets: Patient Outlook is an update to Frost & Sullivan’s coverage of colorectal cancer. In this research service, Frost & Sullivan's expert analysts examine the patient population for colorectal cancer, 2003-2013. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis:
Colorectal Cancer: Third Leading Cancer in the United States According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer in the United States in both men and women, and leads to the death of more than 55,000 people every year. Treatment is complex, with new product advances in both cytotoxic and targeted therapy drugs changing the landscape of options and pathways utilized by physicians to fight the disease. Like all cancer patients, those affected by colorectal cancer are divided according to factors such as disease progression and line of therapy. Proper understanding of the potential scope of these relative patient groups is important to judge the appropriate market size available for oncology products targeting colorectal cancer. With respect to therapies, adjuvant therapy is typically reserved until patients reach stage III of disease progression. Rectal cancer patients typically receive surgery, radiation therapy, and chemotherapy, while colon cancer patients just receive chemotherapy and surgery. "The percentage of patients receiving chemotherapy is increasing for both rectal and colon cancer patients and this trend combined with an aging patient population is expected to lead to the growth of the adjuvant therapy patient population," notes the analyst of this research service. "It is anticipated that by 2013, approximately 93 percent of stage III rectal cancer patients and 85 percent of stage III colon cancer patients will receive chemotherapy." Increasing Percentage of Stage IV Patients Accepting Pharmaceutical Treatment Stage IV colon and rectal cancers are normally treated with multiple modalities such as surgery, radiation, and pharmaceuticals or any combination of the three. Patient preference of the type of treatment is often followed due to the low survival rate of this end-stage disease. The five-year survival rate is a low 9.8 percent for patients diagnosed with stage IV cancer, and as a result, some patients do not wish to undergo intensive therapy. The projection through 2013 shows an increasing percentage of patients willing to accept treatment through pharmaceuticals. Going by the base year trends, approximately 74 percent of stage IV rectal cancer patients and 53 percent of stage IV colon cancer patients are estimated to take pharmaceuticals as part of their treatment in 2013. "Through 2013, population factors are expected to contribute to positive growth in the population for colorectal cancer, despite the fact that the incidence of colon and rectal cancers are declining slightly," says the analyst. "New treatments are expected to give Stage-IV patients new options in the second/third line of treatment, thus contributing to positive growth for those lines." |
More United States Oncology/Hematology Reports
2012 US Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 620-page analysis of the US tumor marker testing market. Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social ...
The 2012 Cancer Diagnostics Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers by
Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...
The 2012 US Cancer Diagnostics Market by
Venture Planning Group
This report presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory practice, as well as key economic, ...
The 2012 CA Tumor Markers: US, Europe, JapanTest Volume, Sales Forecasts and Supplier Shares by Country by
Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...
Abraxane (Breast Cancer) - Analysis and Forecasts to 2020 by
GlobalData
Abraxane (Breast Cancer) - Analysis and Forecasts to 2020 Summary GlobalData’s pharmaceuticals report, “Abraxane (Breast Cancer) - Analysis and Forecasts to 2020” provides Abraxane sales forecasts for ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
